Patents by Inventor Satenig Guler

Satenig Guler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS
    Publication number: 20240025922
    Abstract: Tetrahydropyrido[3,4-d]pyrimidines compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly humans. The compounds have a chemical structure of the general Formula (I), (II), (III), (IV) or (V) or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 8, 2023
    Publication date: January 25, 2024
    Inventors: Momar TOURE, Bin LI, Constantin NEAGU, Yanping WANG, Theresa JOHNSON, Andrea UNZUE LOPEZ, Yufang XIAO, Emily FRIIS, Maria DIPOTO, Satenig GULER
  • Compounds and methods for treating bacterial infections
    Patent number: 11046694
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 29, 2021
    Assignee: Entasis Therapeutics, Inc.
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
  • COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20200165251
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Application
    Filed: May 8, 2018
    Publication date: May 28, 2020
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
  • ?-lactamase inhibitor compounds
    Patent number: 9623014
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • BETA-LACTAMASE INHIBITOR COMPOUNDS
    Publication number: 20160175290
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • Beta-lactamase inhibitor compounds
    Patent number: 9309245
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 12, 2016
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
  • Beta-Lactamase Inhibitor Compounds
    Publication number: 20150073011
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 12, 2015
    Applicant: ASTRAZENECA AB
    Inventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
  • 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same
    Publication number: 20060264460
    Abstract: The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.
    Type: Application
    Filed: May 18, 2006
    Publication date: November 23, 2006
    Applicant: Wyeth
    Inventors: Neal Green, Yonghan Hu, Neelu Kaila, Kristin Janz, Jennifer Thomason, Huan-Qiu Li, Rajeev Hotchandani, Junjun Wu, Ariamala Gopalsamy, Steve Tam, Lih-Ling Lin, John Cuozzo, Satenig Guler, Adrian Huang, Jeffrey condon